NightShares 500 1x/1.5x ETF NSPL 深 沪
等待开盘 04-02 09:30:00 美东时间
35.57
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 35.57
- 总市值 711.40万
- 52周最高 36.43
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 26.2563
- 委 比 0.00%
- 总股本 20.00万
- 历史最高 36.43
- 量 比 0
- 振 幅 0.00%
- 历史最低 26.2563
- 每 手 1
- 风险率 0.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At Uchicago Medicine
BRIEF-Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At Uchicago Medicine March 16 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O : ELEDON ANNOUNCES UPDATED DATA FROM INVESTIGATOR-INITIATED ISLET TRANSPLANT TRIAL OF TEG
03-16 19:38
BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant
Nov 18 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O: ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLE...
2025-11-19 05:36
BRIEF-Tonix, Mass General Partner on Phase 2 Trial of TNX-1500 to Prevent Kidney Transplant Organ Rejection
Nov 4 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES COLLABORATION WITH MASSACHUSETTS GENERAL HOSPITAL TO ADVANCE PHASE 2 CLINICAL TRIAL OF DIMERIC FC-MODIFIED ...
2025-11-04 20:31
BRIEF-Moderna Announces Phase 3 Study Of Investigational Cytomegalovirus (Cmv) Vaccine Did Not Meet Primary Efficacy Endpoint
Oct 22 (Reuters) - Moderna Inc MRNA.O: MODERNA ANNOUNCES PHASE 3 STUDY OF INVESTIGATIONAL CYTOMEGALOVIRUS (CMV) VACCINE DID NOT MEET PRIMARY EFFICACY ENDPOINT MODERNA - TO DISCONTINUE DEVELOPMENT OF M...
2025-10-23 04:52
BRIEF-Imdx Welcomes New VP Marketing To Prepare For Commercial Transplant Assay Launch
Oct 13 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O: IMDX WELCOMES NEW VP MARKETING TO PREPARE FOR COMMERCIAL TRANSPLANT ASSAY LAUNCH Source text: ID:nGNX77nZY0 Further company coverage: IMDX....
2025-10-14 04:18
BRIEF-Imdx Reports kidney transplant patient achieved ‘immune reset’ with novel therapy and graftassure monitoring
Oct 6 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O: IMDX REPORTS KIDNEY TRANSPLANT PATIENT ACHIEVED ‘IMMUNE RESET’ WITH NOVEL THERAPY AND GRAFTASSURE MONITORING Source text: ID:nGNXYFDTG Furth...
2025-10-06 19:19
BRIEF-TECVAYLI And DARZALEX FASPRO Induction Shows Strong Response In Newly Diagnosed, Transplant-Eligible Myeloma Patients
Sept 19 (Reuters) - Johnson & Johnson JNJ.N: TECVAYLI® AND DARZALEX FASPRO®-BASED INDUCTION TREATMENT DEMONSTRATES PROMISING RATES AND DEPTHS OF RESPONSE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIA...
2025-09-19 20:43
BRIEF-FibroBiologics Advances Bone Marrow Organoid Tech for Cancer & Immune Therapies
Sept 10 (Reuters) - Fibrobiologics Inc FBLG.O: FIBROBIOLOGICS ANNOUNCES SIGNIFICANT ADVANCEMENTS IN BONE MARROW ORGANOID PLATFORM ENABLING DEVELOPMENT FOR CANCER AND IMMUNE-RELATED THERAPIES FIBROBIOL...
2025-09-10 20:39
BRIEF-Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Sept 8 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A: LINEAGE CELL THERAPEUTICS INITIATES CELL TRANSPLANT PROGRAM IN TYPE 1 DIABETES Source text: ID:nBwb4CvZSa Further company coverage: LCTX.A ((Re...
2025-09-08 20:03
BRIEF-CareDx Submits Comment Letter On Draft LCD For Molecular Testing For Solid Organ Transplant Rejection
Sept 2 (Reuters) - CareDx Inc CDNA.O: CAREDX- SUBMITS COMMENT LETTER ON DRAFT LCD FOR MOLECULAR TESTING FOR SOLID ORGAN TRANSPLANT REJECTION Source text: ID:nBw4TBHR6a Further company coverage: CDNA.O...
2025-09-03 05:37
